查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100167

被忽視的熱帶疾病診斷市場：2026-2032年全球市場預測

Neglected Tropical Diseases Diagnosis Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

被忽視的熱帶疾病診斷市場預計到 2032 年將成長至 112.7 億美元，複合年成長率為 6.05%。

主要市場統計數據
基準年 2025 74.7億美元
預計年份：2026年 79.4億美元
預測年份 2032 112.7億美元
複合年成長率 (%) 6.05%

隨著各國加強檢測、治療和阻斷登革熱、南美錐蟲病、利什曼原蟲症、血吸蟲病、土源性蠕蟲病、沙眼、盤尾絲蟲病和非洲錐蟲病等感染疾病的傳播途徑，被忽視的熱帶疾病的診斷正成為一項公共衛生重點。世界衛生組織（世衛組織）將被忽視的熱帶疾病定義為一組疾病，這些疾病對熱帶和亞熱帶地區的人口，特別是那些缺乏衛生設施、清潔用水、病媒控制和初級醫療保健的社區，造成了不成比例的影響。準確、快速且易於取得的現場診斷對於個案管理、監測、根除計畫、集體爆發應對和根除後監測至關重要。診斷方法包括顯微鏡檢查、血清學檢測、抗原檢測、分子檢測、快速診斷測試、影像評估和新型數位工具。需求受到即時檢測、多參數檢測平台、品質保證的監測系統以及即使在資源匱乏的環境下也能可靠運作的診斷方法等因素的影響。綜合疾病管理、合理使用抗生素、氣候敏感型監測和跨境防範等政策優先事項，正在強化診斷方法在流行地區和非流行地區的戰略作用。

神經管缺陷診斷領域的變革性變化

被忽視的熱帶疾病（NTD）的診斷方法正從以疾病特異性、以檢查室為中心的傳統工作流程轉向分散式、綜合性、與監測相結合的檢測模式。傳統上，許多NTD計畫依賴臨床症狀、顯微鏡檢查或單一病原體檢測，這些方法面臨許多挑戰，例如在低感染率情況下靈敏度低、負責人專業水平參差不齊，以及難以區分既往感染和當前性行為感染。目前的變革得益於快速診斷檢測（用於第一線篩檢）、核酸擴增技術（用於確診）、數位報告系統（用於即時監測）以及能夠從單一檢體中檢測多種病原體的綜合平台。氣候變遷、都市化、人口遷移、森林砍伐以及媒介生態系統的變化也在影響疾病的分佈，使得在傳統流行區域以外進行診斷變得特別重要。醫療衛生系統正日益將NTD檢測與婦幼保健項目、血液安全、媒介傳播疾病監測、移民健康和集體爆發防治等工作結合。同時，隨著根除淋巴絲蟲病、沙眼、亞茲氏症和盤尾絲蟲病等疾病的努力不斷推進，人們越來越需要能夠確認傳播阻斷並檢測疾病復發的特異性極高的工具。籌資策略正轉向品質有保證、價格合理、便攜易用且能夠支持個體臨床判斷和人群監測的檢測方法。

人工智慧對神經管缺陷診斷的累積影響

人工智慧 (AI) 透過改善影像判讀、疫情預測、分診和監測資訊分析，為被忽視的熱帶疾病 (NTD) 的診斷增添了新的能力。 AI 驅動的顯微鏡和電腦視覺技術有助於識別寄生蟲、蟲卵、媒介、皮膚病變、眼部觀察和血液塗片異常，從而減少對數量有限的放射科專家的依賴。機器學習模型也被用於整合流行病學、氣候、地理空間、人口遷移和醫療保健系統數據，以識別媒介傳播疾病和寄生蟲疾病的高風險地區。在診斷檢查室中，AI 可以輔助品管、自動模式識別、最佳化工作流程，並提高影像密集和訊號型偵測結果判讀的一致性。在現場，基於智慧型手機的影像診斷、數位決策支援和雲端報告可以提高病例檢出率，並縮短檢查、治療和公共衛生反應的時間。然而，人工智慧的累積效應取決於高品質的訓練資料集、透明的檢驗、來自流行地區人群的代表性資料、隱私保護、與公共衛生系統的互通性以及清晰的法律規範。在被忽視的熱帶疾病（NTD）的診斷中，人工智慧的價值在於它能夠補充檢驗的檢測方法、增強現場能力並提高監測的公平性，而不是取代最終的臨床和實驗室判斷。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

由於亞太地區人口稠密，地方性流行區眾多，檢測基礎設施不斷完善，且多個次區域仍面臨登革熱、土源性蠕蟲病、淋巴絲蟲病、麻風病、恙蟲病樣熱症候群以及食源性吸蟲感染疾病等疾病的持續風險，因此該地區在被忽視的熱帶病診斷方面仍然至關重要。在南亞和東南亞，快速檢測、分子診斷和發燒疾病綜合監測是重點，旨在加強早期發現。在北美，由於旅遊醫學、移民健康管理、捐血篩檢、輸入性感染疾病以及南美錐蟲病和其他媒介傳播疾病的傳播等區域特有的風險，診斷情況有所不同。該地區的學術機構和公共衛生實驗室支持確診檢測、標準診斷和檢測方法檢驗。在拉丁美洲，南美錐蟲病、利什曼原蟲症、屈公病、茲卡熱、土源性蠕蟲病和其他寄生蟲感染疾病至關重要，診斷重點在於先天性篩檢、慢性病檢測、病媒監測以及在服務不足地區提供確診檢測。在歐洲，診斷需求日益與輸入性被忽視的熱帶疾病、移民篩檢、參考檢查室網路、旅行相關感染疾病以及地中海地區和其他高風險地區的氣候相關病媒監測密切相關。在中東，迫切需要針對利什曼原蟲症、特定地區的血吸蟲病、旅行相關感染疾病、衝突引發的流離失所和跨境人口流動進行診斷，這凸顯了快速部署和具備監測功能的檢測工具的重要性。非洲是世界上被忽視的熱帶疾病負擔最重的地區之一，這些疾病包括血吸蟲病、盤尾絲蟲病、淋巴絲蟲病、沙眼、土源性蠕蟲病、利什曼原蟲症和非洲錐蟲病。該地區的診斷重點包括即時檢測、疾病分佈圖繪製工具、根除檢驗、改善檢體運輸以及與基層醫療保健和社區計畫的整合。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協地區，被忽視的熱帶疾病診斷受到登革熱監測、淋巴絲蟲病根除工作、土源性寄生蟲控制、麻風病檢測以及熱帶和群島地區跨境流動的顯著影響。該地區的公共衛生計畫日益需要快速、經濟且數位連接的診斷方法，以支持地方層級的篩檢和集體爆發應對。在海灣合作理事會（GCC）國家，儘管許多典型被忽視的熱帶疾病的流行負擔相對較低，但對診斷的需求主要來自移徙工人的健康、旅遊醫學、輸入性寄生蟲感染疾病、該地區部分地區的利什曼原蟲症，以及先進醫療體系對可靠檢測和確診的需求。在歐盟，鑑於埃及斑蚊和其他媒介蚊蟲已擴散到易感環境中，協調一致的監測、參考檢測實驗室之間的協調、對移徙者和旅行者的篩檢以及對媒介傳播疾病的防範工作尤為重要。金磚國家在被忽視的熱帶疾病（NTD）診斷方面涵蓋頻譜廣泛，其中巴西、印度、中國和南非承擔著主要地方性疾病和監測重點，而俄羅斯則更側重於輸入性感染疾病、區域性寄生蟲病以及檢測系統的發展。七國集團（G7）主要透過診斷調查、監管標準、全球衛生資金籌措、監測科學和輸入性感染疾病的管理，以及應對與氣候變遷和移民相關的國內風險，對此領域產生影響。北約成員國雖然並非以衛生市場為導向的組織，但在軍事部署、部隊健康保護、人道主義行動、疫情防範和NTD暴露風險較高的地區的生物監測方面，它們也面臨著至關重要的診斷問題。

針對主要被忽視的熱帶疾病診斷環境的關鍵國家特定見解

在美國，恰加斯病篩檢、旅行相關感染疾病、移民健康、標準實驗室檢測和媒介傳播疾病監測是導致被忽視的熱帶疾病診斷的關鍵因素。加拿大也同樣優先應對輸入性感染疾病，尤其著重於檢查室為基礎的確診和公共衛生報告。在墨西哥，南美錐蟲病、利什曼原蟲症、登革熱和土源性蠕蟲病的檢測需要兼顧國內和國際需求。而巴西則是南美錐蟲病、利什曼原蟲症、血吸蟲病、痲瘋病和其他熱帶感染疾病的主要診斷中心，這些疾病需要分散式檢查和參考檢測來確診。英國、德國、法國、義大利和西班牙則著重於輸入性被忽視的熱帶疾病、移民篩檢、旅遊醫學和參考診斷，而南歐國家也監測某些蟲媒病毒和寄生蟲疾病的媒介適宜性和地方性傳播風險。俄羅斯的診斷重點包括輸入性感染疾病、某些地方性寄生蟲疾病，以及在其幅員遼闊、生態條件多樣的地區建立實驗室系統。中國在防治多種地方性疾病方面取得了顯著進展，正在加強寄生蟲疾病監測，並繼續優先發展血吸蟲病監測、媒介傳播疾病監測和先進實驗室能力。印度仍然是被忽視的熱帶疾病（NTD）診斷最重要的國家之一，致力於根除淋巴絲蟲病、控制內臟利什曼原蟲症、監測登革熱和屈公病、開展土源性蠕蟲病控制項目以及麻風病檢測。日本的需求主要集中在旅遊醫學、輸入性感染疾病控制、先進檢查室診斷和公共衛生緊急準備。澳洲將旅行相關NTD的診斷與參與太平洋地區的區域衛生安全以及關注影響偏遠和醫療服務不足社區的感染疾病相結合。韓國的優先事項包括檢測輸入性熱帶疾病、先進的分子診斷、軍事和旅行者健康，以及在全球互聯的醫療保健系統中發展監測系統。

為神經管缺陷診斷領域的領導者提供的實用建議

產業領導者應優先考慮經過臨床檢驗、價格合理、易於部署且適合在地方性流行地區分散使用的診斷方法。產品策略應著重於低強度感染的靈敏度、根除檢驗的特異性、耐熱試劑、簡化的檢體製備以及與資源受限基礎設施的兼容性。開發人員應投資開發與被忽視的熱帶疾病綜合防治計畫和發燒性疾病監測一致的多項檢測，並確保檢測結果能夠與國家報告系統關聯。與衛生署、參考實驗室、學術機構、地方衛生網路和全球衛生計畫合作對於現場檢驗、確定性證明和推廣至關重要。領導者應制定以國際性能標準、外部品質評估、上市後監測和創建透明證據為中心的監管和品管策略。數位化整合應作為一項核心功能，包括連接性、離線功能、地理標記監測、隱私保護以及與公共衛生平台的互通性。對於人工智慧驅動的診斷技術，各機構必須使用代表性的資料集，在流行地區進行前瞻性檢驗，記錄模型在不同人群中的表現，並納入人工監督。最後，成功的商業化和對公共衛生的影響需要分階段的准入模式、現場培訓、供應鏈韌性，以及能夠減少偏遠地區斷貨的生產和分銷策略。

調查方法

本執行摘要採用二手研究方法，基於全球衛生機構、同行評審的科學文獻、國家公共衛生機構、疾病根除計畫、監管指南和國際監測資源等公開、檢驗且有數據支持的資訊來源。此方法強調對流行病學、診斷技術、公共衛生政策、區域疾病控制重點和實施挑戰等方面的證據進行三角調查方法。資訊來源檢驗優先考慮時效性、調查方法透明度、機構可信度以及與被忽視的熱帶疾病（NTD）診斷的相關性。本分析不涉及市場規模、市場佔有率和預測，而是著重於與疾病負擔、診斷流程、技術應用、監測需求和區域健康照護重點相關的定性和實證見解。透過繪製已知的NTD流行模式、根除目標、遷移趨勢、檢查室能力和公共衛生應對要求，整合了區域、群體和國家層面的具體見解。技術評估檢視了顯微鏡檢查、血清學檢測、抗原檢測、分子診斷、快速診斷測試、數位健康和​​人工智慧的作用，同時也考慮了成本效益、可及性、人員能力、檢體運輸、品質保證和法規檢驗性等實際限制因素。

結論

被忽視的熱帶疾病（NTD）的診斷正從分散的、針對特定疾病的檢測轉向整合的、去中心化的、數據驅動的診斷生態系統。最大的機會在於能夠支持早期病例發現、集體爆發應對、根除檢驗以及為服務不足的社區提供公平獲取途徑的工具。各區域的需求差異很大。非洲和亞太地區需要可擴展的即時檢測和與監測系統相連的診斷方法，以應對疾病負擔沉重的環境。拉丁美洲需要更強大的檢測工具來檢測南美錐蟲病、利什曼原蟲症、蟲媒病毒和先天性風險。歐洲和北美則著重於輸入性感染疾病、移民健康和氣候敏感型監測。中東需要適用於人口流動、流離失所和地方性疾病的可部署診斷方法。人工智慧、多參數檢測、數位化報告和分子診斷平台，如果經過負責任的檢驗並在品質保證框架下實施，可以提高診斷準確性和公共衛生應對力。將創新與公共衛生優先事項、可負擔性、實際應用和可互通的監測相結合的行業相關人員，將最有利於提高控制和根除被忽視的熱帶疾病的有效性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：被忽視的熱帶疾病診斷市場：依疾病類型分類

  • 南美錐蟲病
    • 酵素免疫分析法（ELISA）
    • 聚合酵素鏈鎖反應
  • 利什曼原蟲症
    • 皮膚利什曼原蟲症檢測
    • 利什曼原蟲症檢測
  • 淋巴絲蟲病
    • 抗體檢測
    • 層析法
  • 盤尾絲蟲病
    • 聚合酵素鏈鎖反應
    • 皮膚切片的顯微鏡檢查
  • 血吸蟲病
    • 糞便的顯微鏡檢查
    • 尿抗原檢測

第8章：被忽視的熱帶疾病診斷市場：依技術分類

  • 免疫測量
    • 化學冷光檢測法
    • 酵素免疫分析法（ELISA）
  • 顯微鏡
    • 螢光顯微鏡
    • 光學顯微鏡
  • 分子診斷
    • 等溫擴增
    • 聚合酵素鏈鎖反應
  • 快速診斷測試
    • 抗體檢測
    • 抗原檢測

第9章：被忽視的熱帶疾病診斷市場：依最終用戶分類

  • 診所
    • 社區健康中心
    • 基層醫療診所
  • 診斷檢查室
    • 獨立檢測實驗室
    • 參考實驗室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構

第10章：被忽視的熱帶疾病診斷市場：依檢測法分類

  • 臨床試驗
  • 即時檢測
  • 自我檢查
  • 現場檢查

第11章：被忽略的熱帶疾病診斷市場：依樣本類型分類

  • 血液檢體
  • 血清檢體
  • 血漿檢體
  • 尿液檢體

第12章：被忽視的熱帶疾病診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：被忽視的熱帶疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 被忽視的熱帶疾病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Chembio Diagnostic Systems, Inc.
  • Coris BioConcept
  • CTK Biotech, Inc.
  • Danaher Corporation
  • DiaSys Diagnostic Systems GmbH
  • Eiken Chemical Co., Ltd.
  • EUROIMMUN Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche Ltd
  • Genome Diagnostics Pvt. Ltd.
  • Hologic, Inc.
  • InBios International, Inc.
  • J. Mitra & Co. Pvt. Ltd.
  • KAINOS Laboratories, Inc.
  • Kyowa Kirin Co., Ltd.
  • Meril Diagnostics Pvt. Ltd.
  • Omega Diagnostics Group PLC
  • OraSure Technologies, Inc.
  • Oscar Medicare Pvt. Ltd.
  • Premier Medical Corporation Ltd.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tulip Diagnostics Pvt. Ltd.
  • ZeptoMetrix, LLC
Product Code: MRR-742BD5181EB6

The Neglected Tropical Diseases Diagnosis Market is projected to grow by USD 11.27 billion at a CAGR of 6.05% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.47 billion
Estimated Year [2026] USD 7.94 billion
Forecast Year [2032] USD 11.27 billion
CAGR (%) 6.05%

Neglected tropical diseases diagnosis is becoming a public health priority as countries intensify efforts to detect, treat, and interrupt transmission of infections such as dengue, Chagas disease, leishmaniasis, lymphatic filariasis, schistosomiasis, soil-transmitted helminthiases, trachoma, onchocerciasis, and human African trypanosomiasis. The World Health Organization recognizes neglected tropical diseases as a diverse group of conditions that disproportionately affect populations in tropical and subtropical regions, particularly communities facing limited access to sanitation, clean water, vector control, and primary healthcare. Accurate, timely, and field-ready diagnostics are central to case management, surveillance, elimination programs, outbreak response, and post-elimination monitoring. The diagnostic landscape spans microscopy, serology, antigen detection, molecular testing, rapid diagnostic tests, imaging-supported assessment, and emerging digital tools. Demand is being shaped by the need for point-of-care testing, multiplex platforms, quality-assured surveillance systems, and diagnostics that perform reliably in resource-constrained environments. Policy emphasis on integrated disease management, antimicrobial stewardship, climate-sensitive surveillance, and cross-border preparedness is reinforcing the strategic role of diagnostics across endemic and non-endemic settings.

Transformative Shifts in the NTD Diagnosis Landscape

The diagnostic landscape for neglected tropical diseases is shifting from disease-specific, laboratory-centered workflows toward decentralized, integrated, and surveillance-linked testing models. Historically, many NTD programs relied on clinical signs, microscopy, or single-pathogen assays, which can be limited by low sensitivity in low-burden infections, variable operator expertise, and challenges in differentiating past exposure from active infection. Current transformation is being driven by rapid diagnostic tests for frontline screening, nucleic acid amplification technologies for confirmatory detection, digital reporting systems for real-time surveillance, and integrated platforms capable of detecting multiple pathogens from a single sample. Climate change, urbanization, population mobility, deforestation, and changes in vector ecology are also influencing disease distribution, making diagnostics important beyond traditionally endemic zones. Health systems are increasingly aligning NTD testing with maternal and child health programs, blood safety, vector-borne disease surveillance, migrant health, and outbreak preparedness. At the same time, the push for elimination of diseases such as lymphatic filariasis, trachoma, yaws, and onchocerciasis is increasing the need for highly specific tools that can verify interruption of transmission and detect recrudescence. Procurement strategies are moving toward quality-assured, affordable, portable, and easy-to-use assays that can support both individual clinical decisions and population-level surveillance.

Cumulative Impact of Artificial Intelligence on NTD Diagnosis

Artificial intelligence is adding a new layer of capability to neglected tropical diseases diagnosis by improving image interpretation, outbreak prediction, triage, and surveillance intelligence. AI-supported microscopy and computer vision can assist in the identification of parasites, eggs, vectors, skin lesions, ocular findings, and blood-smear abnormalities, helping reduce dependence on scarce expert readers. Machine learning models are also being used to combine epidemiological, climatic, geospatial, mobility, and health-system data to identify high-risk areas for vector-borne and parasitic diseases. In diagnostic laboratories, AI can support quality control, automate pattern recognition, optimize workflows, and improve interpretation consistency for image-heavy or signal-based assays. In field settings, smartphone-enabled imaging, digital decision support, and cloud-connected reporting can strengthen case detection and shorten the time between testing, treatment, and public health action. However, the cumulative impact of AI depends on high-quality training datasets, transparent validation, representative data from endemic populations, privacy safeguards, interoperability with public health systems, and clear regulatory pathways. For NTD diagnosis, AI is most valuable when it complements validated tests, strengthens frontline capacity, and improves surveillance equity rather than replacing confirmatory clinical and laboratory judgment.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific remains central to neglected tropical diseases diagnosis due to the coexistence of high-population endemic settings, expanding laboratory infrastructure, and persistent risks from dengue, soil-transmitted helminths, lymphatic filariasis, leprosy, scrub typhus-like febrile syndromes, and foodborne trematode infections in several subregions. Countries across South and Southeast Asia are emphasizing rapid testing, molecular confirmation, and integrated febrile illness surveillance to strengthen early detection. North America has a different diagnostic profile, shaped by travel medicine, migrant health, blood donor screening, imported infections, and localized risks such as Chagas disease and vector-borne disease expansion. Academic and public health laboratories in the region support confirmatory testing, reference diagnostics, and assay validation. Latin America is highly relevant for Chagas disease, leishmaniasis, dengue, chikungunya, Zika, soil-transmitted helminths, and other parasitic infections, with diagnostic priorities centered on congenital screening, chronic disease detection, vector surveillance, and access to confirmatory testing in underserved areas. Europe's diagnostic needs are increasingly linked to imported NTDs, migrant screening, reference laboratory networks, travel-related infections, and climate-driven vector surveillance in Mediterranean and other receptive areas. The Middle East faces diagnostic demand associated with leishmaniasis, schistosomiasis in selected settings, travel-linked infections, conflict-related displacement, and cross-border population movement, making deployable and surveillance-ready tools important. Africa carries one of the heaviest NTD burdens globally, including schistosomiasis, onchocerciasis, lymphatic filariasis, trachoma, soil-transmitted helminths, leishmaniasis, and human African trypanosomiasis; the region's diagnostic priorities include point-of-care testing, mapping tools, elimination verification, specimen transport improvements, and integration with primary healthcare and community-based programs.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, neglected tropical diseases diagnosis is strongly influenced by dengue surveillance, lymphatic filariasis elimination activities, soil-transmitted helminth control, leprosy detection, and cross-border mobility across tropical and archipelagic settings. The region's public health programs increasingly require rapid, affordable, and digitally connected diagnostics to support community-level screening and outbreak response. The GCC has a comparatively lower endemic burden for many classic NTDs, but diagnostic demand is supported by migrant worker health, travel medicine, imported parasitic infections, leishmaniasis in parts of the region, and the need for strong laboratory confirmation within advanced healthcare systems. The European Union emphasizes harmonized surveillance, reference laboratory coordination, migrant and traveler screening, and vector-borne disease preparedness as Aedes mosquitoes and other vectors expand into receptive environments. BRICS countries collectively represent a broad NTD diagnostic spectrum, with Brazil, India, China, and South Africa contributing major endemic and surveillance priorities, while Russia's focus is more concentrated on imported infections, regional parasitic diseases, and laboratory preparedness. G7 countries primarily influence the field through diagnostic research, regulatory standards, global health financing, surveillance science, and imported disease management, while also addressing domestic risks linked to climate change and migration. NATO members, although not a health-market grouping, have relevant diagnostic considerations related to military deployment, force health protection, humanitarian operations, outbreak preparedness, and bio-surveillance in regions where NTD exposure risk is operationally significant.

Key Country Insights Across Major NTD Diagnostic Settings

In the United States, neglected tropical diseases diagnosis is shaped by Chagas disease screening, travel-associated infections, migrant health, reference laboratory testing, and vector-borne disease surveillance, while Canada faces similar imported infection priorities with strong emphasis on laboratory confirmation and public health reporting. Mexico combines domestic and cross-border needs for Chagas disease, leishmaniasis, dengue, and soil-transmitted helminth detection, while Brazil is a major diagnostic setting for Chagas disease, leishmaniasis, dengue, schistosomiasis, leprosy, and other tropical infections requiring both decentralized testing and reference confirmation. The United Kingdom, Germany, France, Italy, and Spain focus on imported NTDs, migrant screening, travel medicine, and reference diagnostics, with southern European countries also monitoring vector suitability and autochthonous transmission risk for some arboviral and parasitic diseases. Russia's diagnostic priorities include imported tropical infections, selected regional parasitic diseases, and laboratory readiness across a large territory with varied ecological conditions. China has strengthened parasitic disease surveillance following major progress against several endemic infections and continues to prioritize schistosomiasis surveillance, vector-borne disease monitoring, and advanced laboratory capacity. India remains one of the most important national settings for NTD diagnosis due to lymphatic filariasis elimination efforts, visceral leishmaniasis control, dengue and chikungunya surveillance, soil-transmitted helminth programs, and leprosy detection. Japan's needs are driven mainly by travel medicine, imported infection management, advanced laboratory diagnostics, and public health preparedness. Australia combines travel-related NTD diagnosis with regional health security engagement in the Pacific and attention to infections affecting remote and underserved communities. South Korea's priorities include imported tropical disease detection, advanced molecular diagnostics, military and travel health, and surveillance readiness in a globally connected health system.

Actionable Recommendations for NTD Diagnostic Leaders

Industry leaders should prioritize diagnostics that are clinically validated, affordable, easy to deploy, and suitable for decentralized use in endemic settings. Product strategies should focus on sensitivity in low-intensity infections, specificity for elimination verification, heat-stable reagents, simple sample preparation, and compatibility with low-resource infrastructure. Developers should invest in multiplex assays that align with integrated NTD programs and febrile illness surveillance, while ensuring that results can be connected to national reporting systems. Partnerships with ministries of health, reference laboratories, academic institutions, community health networks, and global health programs are essential for field validation, implementation evidence, and adoption. Leaders should build regulatory and quality-management strategies around international performance standards, external quality assessment, post-market surveillance, and transparent evidence generation. Digital integration should be treated as a core capability, including connectivity, offline functionality, geotagged surveillance, privacy protection, and interoperability with public health platforms. For AI-enabled diagnostics, organizations should use representative datasets, conduct prospective validation in endemic environments, document model performance across populations, and include human oversight. Finally, successful commercialization and public health impact require tiered access models, local training, supply-chain resilience, and manufacturing or distribution approaches that reduce stockouts in remote areas.

Research Methodology

This executive summary is developed using a secondary research methodology grounded in publicly available, verifiable, and data-backed sources from global health authorities, peer-reviewed scientific literature, national public health agencies, disease elimination programs, regulatory guidance, and international surveillance resources. The approach emphasizes triangulation of evidence across epidemiology, diagnostic technology, public health policy, regional disease priorities, and implementation challenges. Source evaluation prioritizes recency, methodological transparency, institutional credibility, and relevance to neglected tropical diseases diagnosis. The analysis excludes market sizing, market share, and forecasting, focusing instead on qualitative and evidence-based insights related to disease burden, diagnostic workflows, technology adoption, surveillance needs, and regional healthcare priorities. Regional, group, and country insights are synthesized by mapping known NTD prevalence patterns, elimination targets, travel and migration dynamics, laboratory capacity, and public health response requirements. Technology assessment considers the role of microscopy, serology, antigen testing, molecular diagnostics, rapid diagnostic tests, digital health, and artificial intelligence, while acknowledging practical constraints such as affordability, access, workforce capacity, sample transport, quality assurance, and regulatory validation.

Conclusion

Neglected tropical diseases diagnosis is moving from fragmented, disease-specific testing toward integrated, decentralized, and data-enabled diagnostic ecosystems. The strongest opportunities lie in tools that support early case detection, outbreak response, elimination verification, and equitable access for underserved communities. Regional needs vary substantially: Africa and Asia-Pacific require scalable point-of-care and surveillance-linked diagnostics for high-burden settings; Latin America needs stronger detection for Chagas disease, leishmaniasis, arboviruses, and congenital risks; Europe and North America focus on imported infections, migrant health, and climate-sensitive surveillance; and the Middle East requires deployable diagnostics suited to mobility, displacement, and localized endemicity. Artificial intelligence, multiplex testing, digital reporting, and molecular platforms can improve diagnostic precision and public health responsiveness when validated responsibly and implemented with quality assurance. Industry participants that align innovation with public health priorities, affordability, field usability, and interoperable surveillance will be best positioned to strengthen NTD control and elimination outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neglected Tropical Diseases Diagnosis Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Chagas Disease
    • 7.2.1. Enzyme Linked Immunosorbent Assay
    • 7.2.2. Polymerase Chain Reaction
  • 7.3. Leishmaniasis
    • 7.3.1. Cutaneous Leishmaniasis Tests
    • 7.3.2. Visceral Leishmaniasis Tests
  • 7.4. Lymphatic Filariasis
    • 7.4.1. Antibody Detection Test
    • 7.4.2. Immunochromatographic Test
  • 7.5. Onchocerciasis
    • 7.5.1. Polymerase Chain Reaction
    • 7.5.2. Skin Snip Microscopy
  • 7.6. Schistosomiasis
    • 7.6.1. Stool Microscopy
    • 7.6.2. Urine Antigen Test

8. Neglected Tropical Diseases Diagnosis Market, by Technology

  • 8.1. Introduction
  • 8.2. Immunoassays
    • 8.2.1. Chemiluminescence Assay
    • 8.2.2. Enzyme Linked Immunosorbent Assay
  • 8.3. Microscopy
    • 8.3.1. Fluorescence Microscopy
    • 8.3.2. Light Microscopy
  • 8.4. Molecular Diagnostics
    • 8.4.1. Isothermal Amplification
    • 8.4.2. Polymerase Chain Reaction
  • 8.5. Rapid Diagnostic Tests
    • 8.5.1. Antibody Detection
    • 8.5.2. Antigen Detection

9. Neglected Tropical Diseases Diagnosis Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
    • 9.2.1. Community Health Centers
    • 9.2.2. Primary Care Clinics
  • 9.3. Diagnostic Laboratories
    • 9.3.1. Independent Laboratories
    • 9.3.2. Reference Laboratories
  • 9.4. Hospitals
    • 9.4.1. Private Hospitals
    • 9.4.2. Public Hospitals
  • 9.5. Research Institutes

10. Neglected Tropical Diseases Diagnosis Market, by Testing Method

  • 10.1. Introduction
  • 10.2. Laboratory Testing
  • 10.3. Point Of Care Testing
  • 10.4. Self Testing
  • 10.5. Field Testing

11. Neglected Tropical Diseases Diagnosis Market, by Sample Type

  • 11.1. Introduction
  • 11.2. Blood Samples
  • 11.3. Serum Samples
  • 11.4. Plasma Samples
  • 11.5. Urine Samples

12. Neglected Tropical Diseases Diagnosis Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Neglected Tropical Diseases Diagnosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neglected Tropical Diseases Diagnosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Becton, Dickinson and Company
  • 16.3. Bio-Rad Laboratories, Inc.
  • 16.4. bioMerieux SA
  • 16.5. Chembio Diagnostic Systems, Inc.
  • 16.6. Coris BioConcept
  • 16.7. CTK Biotech, Inc.
  • 16.8. Danaher Corporation
  • 16.9. DiaSys Diagnostic Systems GmbH
  • 16.10. Eiken Chemical Co., Ltd.
  • 16.11. EUROIMMUN Medizinische Labordiagnostika AG
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Genome Diagnostics Pvt. Ltd.
  • 16.14. Hologic, Inc.
  • 16.15. InBios International, Inc.
  • 16.16. J. Mitra & Co. Pvt. Ltd.
  • 16.17. KAINOS Laboratories, Inc.
  • 16.18. Kyowa Kirin Co., Ltd.
  • 16.19. Meril Diagnostics Pvt. Ltd.
  • 16.20. Omega Diagnostics Group PLC
  • 16.21. OraSure Technologies, Inc.
  • 16.22. Oscar Medicare Pvt. Ltd.
  • 16.23. Premier Medical Corporation Ltd.
  • 16.24. QIAGEN N.V.
  • 16.25. QuidelOrtho Corporation
  • 16.26. Siemens Healthineers AG
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. Tulip Diagnostics Pvt. Ltd.
  • 16.29. ZeptoMetrix, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHAGAS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHAGAS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHAGAS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LEISHMANIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LEISHMANIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LEISHMANIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CUTANEOUS LEISHMANIASIS TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CUTANEOUS LEISHMANIASIS TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CUTANEOUS LEISHMANIASIS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VISCERAL LEISHMANIASIS TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VISCERAL LEISHMANIASIS TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VISCERAL LEISHMANIASIS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LYMPHATIC FILARIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LYMPHATIC FILARIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LYMPHATIC FILARIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DETECTION TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DETECTION TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DETECTION TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOCHROMATOGRAPHIC TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOCHROMATOGRAPHIC TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOCHROMATOGRAPHIC TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCHOCERCIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCHOCERCIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCHOCERCIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SKIN SNIP MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SKIN SNIP MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SKIN SNIP MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STOOL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STOOL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STOOL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL URINE ANTIGEN TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL URINE ANTIGEN TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL URINE ANTIGEN TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMILUMINESCENCE ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMILUMINESCENCE ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMILUMINESCENCE ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RAPID DIAGNOSTIC TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RAPID DIAGNOSTIC TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RAPID DIAGNOSTIC TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBODY DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBODY DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBODY DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIGEN DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIGEN DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIGEN DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SELF TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SELF TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SELF TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL FIELD TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL FIELD TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL FIELD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SERUM SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SERUM SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SERUM SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLASMA SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PLASMA SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLASMA SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL URINE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL URINE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL URINE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 276. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 277. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 280. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 281. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2